Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mnat Capital LLC is currently active in the Biotechnology & Pharmaceuticals technology area, where the portfolio includes 1 pending office action. This action represents the current focus of the patent prosecution efforts. The application is being reviewed within 1 distinct art unit, which indicates that the technology is classified under a specific set of examination guidelines.
The prosecution is overseen by 1 distinct examiner, SALVOZA, M FRANCO G. This examiner is the busiest for the portfolio, as they are currently responsible for 1 pending office action. Having a specific examiner for the pending work means that the success in this technology area is currently tied to the discretion and prior art interpretations of this individual.
Practitioners should analyze the previous decisions made by SALVOZA, M FRANCO G within the 1 distinct art unit to anticipate potential hurdles. Since there is 1 pending office action, the resources can be dedicated to addressing the specific concerns of this examiner. The outcome of this Biotechnology & Pharmaceuticals application will set a precedent for any future filings in this technical space.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569589 | TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES | SALVOZA, M FRANCO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569589 | TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569589 | TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES | SALVOZA, M FRANCO G | 1672 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMnat Capital LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
M Franco G Salvoza has the most, with 1 of Mnat Capital LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.